🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Custirsen, paclitaxel and carboplatin

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  2. Cyclophosphamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 1 small molecule active

    1 trial

  3. Cyclophosphamide and Fludarabine

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer, Nonsmall Cell, Recurrent

    phase 1 small molecule active

    1 trial

  4. DABRAFENIB MESYLATE, TMT212, CANAKINUMAB, DKY709, LXH254, TRAMETINIB DIMETHYL SULFOXIDE, NIR178, MCS110, LXH254, INC280, TMT212, PDR001, NIR178, PDR001, NIZ985, TRAMETINIB DIMETHYL SULFOXIDE, LAG525, NIR178, LXH254, DABRAFENIB MESYLATE

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 1 small molecule active

    1 trial

  5. DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy

    Boehringer Ingelheim

    relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

    phase 1 other active

    1 trial

  6. DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

    Boehringer Ingelheim

    Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

    phase 1 other active

    1 trial

  7. DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer

    Boehringer Ingelheim

    Extensive-stage small cell lung carcinoma (ES-SCLC)

    phase 1 other active

    1 trial

  8. DCVac-L

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 1 mab completed

    1 trial

  9. DS-1205c

    Daiichi Sankyo

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule terminated

    1 trial

  10. DT2216

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  11. Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

    Alphapharm Pty Ltd

    Small cell lung cancer

    phase 1 other active

    1 trial

  12. Demcizumab

    Mereo BioPharma Group plc

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  13. Dendritic Cell (DC1) Vaccine

    VACCINEX, INC.

    HER2-positive Breast Cancer

    phase 1 mab active

    1 trial

  14. Dendritic Cell Vaccination

    Quantum Biopharma

    Metastatic Breast Cancer

    phase 1 mab active

    1 trial

  15. Docetaxel

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  16. Dose escalation trial of BNT152+153 in patients with cancer

    BioNTech SE

    Various solid tumors that are metastatic or unresectable

    phase 1 other active

    1 trial

  17. Drug Product De-TIL-0255

    Nurix Therapeutics

    Platinum-resistant Ovarian Cancer

    phase 1 mab terminated

    1 trial

  18. Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  19. E7080

    Eisai Co.,

    Cancer: Solid Tumors

    phase 1 small molecule completed

    1 trial

  20. ELVN-002

    Enliven Therapeutics

    HER2-positive Breast Cancer

    phase 1 small molecule active

    1 trial

  21. ELVN-002

    Enliven Therapeutics

    HER2 Mutant Non-small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  22. EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers

    Eli Lilly Co.

    Breast Cancer, Endometrial cancer

    phase 1 other active

    1 trial

  23. ENMD-2076

    CASI Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  24. ES414

    Aptevo Therapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources